MI-EATON
14.7.2020 23:39:14 CEST | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group has been leveraging advanced Industry 4.0 technology to help its global operations safely navigate the ongoing COVID-19 crisis and continue to service its customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714006047/en/
Eaton’s Vehicle Group envisions Industry 4.0 as both operational and informational technologies, enabling autonomous production systems that are connected, optimized, transparent, proactive, and agile. Supported by an integrated ecosystem, the technologies are composed of augmented reality, rapid application development, autonomous robots, digital simulation, and additive manufacturing.
“I’m proud of our Vehicle Group team and their ingenuity, especially during the COVID-19 pandemic,” said João Faria, president, Vehicle Group. “By leveraging augmented reality, we are able to continue to support our operations remotely and continue the development of new products, ensuring our customer deadlines are met despite the global challenges we are all facing.”
Here are examples of how the Vehicle Group is using Industry 4.0 technologies:
Displaying 3D images and connecting remotely to improve safety
To enable remote assistance and critical activities, Vehicle Group teams are using Microsoft’s HoloLens 2 augmented reality goggles that offer the capability to display 3D images in physical spaces and connect remotely. This remote assistance technology ensures that ongoing work can be performed while keeping everyone safe.
Enhancing training and expediting review processes through augmented reality
Augmented reality also assists with knowledge retention and ongoing training. For instance, the Vehicle Group identified an opportunity to use the technology to train operators and engineers on new equipment, which would have traditionally been conducted by instructors who travel to the various remote sites. Additionally, the technology has proven critical for recent customer reviews and approvals.
Analyzing data to reduce costs, improve quality and reduce lead times
Eaton’s Vehicle Group is interconnecting plant systems and machines to collect, analyze and report real-time information, which optimizes plant floor management and provides visibility to real-time production issues in order to address them right away. These efforts are designed to reduce lead times; maintenance, repair and operations (MRO), inventory, indirect-labor/direct-labor costs; as well as increase performance and improve quality.
Implementing robots to promote safe distancing and increase productivity
To optimize manufacturing flow and eliminate the need for forklifts and other human-operated transport machinery, the Vehicle Group is using autonomous automated guided vehicles (AGVs) or autonomous mobile robots (AMRs). In addition to improving the flow of materials throughout a manufacturing facility, AMRs and autonomous AGVs increase safety and allow for social distancing while also lowering costs.
COBOTs, which are robots intended to interact with humans in a shared space or to work safely in close proximity, are being used to safely handle complex and repetitive tasks. This results in improved consistency and accuracy during the manufacturing process.
Using digital simulation to improve production efficiency
Another way the Vehicle Group is increasing productivity is by using digital simulation applications to define which solution and/or combination of factors will result in the highest output. These applications can run several scenarios by changing parameters, such as the number of operators, work in process material, cycle times, operator standardized work and many others. The applications are being used to define new manufacturing cells and assembly lines or to redesign existing ones. In most cases, the Vehicle Group is seeing productivity increase from 10 to 30 percent via higher production output or reduced amount of investment needed.
Leveraging 3D printing tools internally to expedite processes
Additive manufacturing is leveraged to improve safety, quality and efficiency by designing and producing tools, poke-yokes and gauges internally on both polymer and metal materials. This allows fast reactions (shorter lead times), reduced purchase costs and highly customized solutions. For example, lead times can be reduced from weeks to days, while reducing costs from thousands to hundreds.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2019 revenues were $21.4 billion, and we sell products to customers in more than 175 countries. We have approximately 95,000 employees. For more information, visit www.eaton.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714006047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
